Health Care & Life Sciences » Pharmaceuticals | RaQualia Pharma Inc.

RaQualia Pharma Inc. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
4,035
3,088
2,343
1,437
2,597
Total Accounts Receivable
60
20
73
58
449
Inventories
47
9
7
7
195
Other Current Assets
222
155
284
304
82
Total Current Assets
4,364
3,272
2,708
1,806
3,322
Net Property, Plant & Equipment
7
85
261
249
216
Total Investments and Advances
2,221
1,800
1,752
1,937
1,503
Intangible Assets
12
15
14
13
10
Other Assets
45
43
17
14
13
Total Assets
6,648
5,216
4,752
4,019
5,064
ST Debt & Current Portion LT Debt
-
140
-
-
-
Accounts Payable
-
-
-
-
2
Income Tax Payable
17
16
15
3
21
Other Current Liabilities
215
266
185
188
126
Total Current Liabilities
233
422
200
190
149
Provision for Risks & Charges
-
-
12
12
12
Deferred Taxes
669
109
26
29
16
Total Liabilities
902
531
238
231
176
Common Equity (Total)
5,746
4,686
4,514
3,788
4,888
Total Shareholders' Equity
5,746
4,686
4,514
3,788
4,888
Total Equity
5,746
4,686
4,514
3,788
4,888
Liabilities & Shareholders' Equity
6,648
5,216
4,752
4,019
5,064

About RaQualia Pharma

View Profile
Address
Daiwa Meieki Building, 8/F
Nagoya Aichi 450
Japan
Employees -
Website http://www.raqualia.co.jp
Updated 09/14/2018
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist.